Global economic costs due to vivax malaria and the potential impact of its radical cure: A modelling study.
<h4>Background</h4>In 2017, an estimated 14 million cases of Plasmodium vivax malaria were reported from Asia, Central and South America, and the Horn of Africa. The clinical burden of vivax malaria is largely driven by its ability to form dormant liver stages (hypnozoites) that can reac...
Main Authors: | Angela Devine, Katherine E Battle, Niamh Meagher, Rosalind E Howes, Saber Dini, Peter W Gething, Julie A Simpson, Ric N Price, Yoel Lubell |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2021-06-01
|
Series: | PLoS Medicine |
Online Access: | https://doi.org/10.1371/journal.pmed.1003614 |
Similar Items
-
Growing evidence of Plasmodium vivax across malaria-endemic Africa.
by: Katherine A Twohig, et al.
Published: (2019-01-01) -
Towards the elimination of Plasmodium vivax malaria: Implementing the radical cure.
by: Kamala Thriemer, et al.
Published: (2021-04-01) -
Primaquine ineligibility in anti-relapse therapy of Plasmodium vivax malaria: the problem of G6PD deficiency and cytochrome P-450 2D6 polymorphisms
by: J. Kevin Baird, et al.
Published: (2018-01-01) -
Primaquine radical cure of <it>Plasmodium vivax</it>: a critical review of the literature
by: John George K, et al.
Published: (2012-08-01) -
Implications of current therapeutic restrictions for primaquine and tafenoquine in the radical cure of vivax malaria.
by: James Watson, et al.
Published: (2018-04-01)